pharmaceutical investing Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial of CTP-692
Angkor Resources Reports University Study Supporting Copper-Molybdenum Porphyry Potential at Andong Bor, Cambodia